Neoplasms

Digestive System Diseases

All Conditions

Blood and Lymph Conditions

Immune System Diseases

Infections

Mouth and Tooth Diseases

Ear, Nose, and Throat Diseases

Rare Diseases

Stomach Neoplasms

Carcinoma

Lymphoma

Lymphoma, T-Cell

Lymphoma, T-Cell, Peripheral

Epstein-Barr Virus Infections

Lymphoma, Large B-Cell, Diffuse

Hodgkin Disease

Virus Diseases

Lymphoma, B-Cell

Nasopharyngeal Carcinoma

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Neoplasms, Glandular and Epithelial

Lymphoma, Non-Hodgkin

Nasopharyngeal Neoplasms

Pharyngeal Neoplasms

Otorhinolaryngologic Neoplasms

Head and Neck Neoplasms

Nasopharyngeal Diseases

Pharyngeal Diseases

Stomatognathic Diseases

Otorhinolaryngologic Diseases

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Stomach Cancer

Lymphosarcoma

Peripheral T-cell Lymphoma

B-cell Lymphoma

Diffuse Large B-Cell Lymphoma

Hodgkin Lymphoma

Antineoplastic Agents

Antirheumatic Agents

All Drugs and Chemicals

Analgesics

Anti-Infective Agents

Cyclophosphamide

Fludarabine

Fludarabine phosphate

Interleukin-2

Sulfamethazine

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

Analgesics, Non-Narcotic

Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISP-Cas9 system and EBV-CTL will be generated in the laboratory (PD-1 Knockout EBV-CTL).

Fludarabine at 30mg/m2 and Cyclophosphamide at 300mg/m2 single dose will be administered 3 days i.v. before cell infusion.

A total of 2 x 10\^7/kg PD-1 Knockout CTL will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.

Interleukin-2 (IL-2) will be given daily( iv) since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit（IU）/day . Patients will receive a total of four cycles of treatment.

To sustain the survival of infused T cells

Baorui Liu, MD

Shu Su, MD

Yang Yang, MD,PhD,MSCR

Jing Yan, MD

Yang Yang

This study will evaluate the safety of PD-1 knockout EBV-CTL cells in treating EBV (Epstein-Barr virus) positive advanced stage malignancies. Blood samples will also be collected for research purposes.

This is a study of CRISPR-Cas9 mediated PD-1 knockout-T cells from autologous origin. Patients are assigned to receive 4 circles of cell therapy. The safety and clinical response are evaluated. Biomarkers and immunological markers are also monitored.

PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies

A Phase I/II Trial of PD-1 Knockout EBV-CTLs for Advanced Stage EBV Associated Malignancies

MD, PhD, MSCR

Spots Global Cancer Trial Database for stage iv gastric carcinoma